Sept 24 (Reuters) - Revelation Biosciences Inc :
* REVELATION BIOSCIENCES: GEMINI INDUCED STATISTICALLY SIGNIFICANT, DOSE DEPENDENT CHANGES IN CIRCULATORY IL-10 AT 2 HOURS POST-DOSE
* REVELATION BIOSCIENCES INC: COMMITTED TO MOVING RAPIDLY INTO PHASE 1B STUDY IN LATE 2024 OF GEMINI
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.